Evidence map›Paper›PMID 35488147›Full record

ArticleCanadian journal of public health = Revue canadienne de sante publique2022

Inequity in insurance coverage for prescription drugs in New Brunswick, Canada.

Busola Ayodele, Elaine Xiaoyu Guo, Arthur Sweetman, G Emmanuel Guindon

Abstract read
In one paragraph

Article in Canadian journal of public health = Revue canadienne de sante publique, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Universal drug coverage for Canada: It's time.Canadian journal of public health = Revue canadienne de sante publique · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Busola AyodeleCentre for Health Economics and Policy Analysis, McMaster University, CRL Building, Room 229, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Elaine Xiaoyu GuoDepartment of Economics, University of Toronto, Toronto, ON, Canada.
Arthur SweetmanCentre for Health Economics and Policy Analysis, McMaster University, CRL Building, Room 229, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
G Emmanuel GuindonCentre for Health Economics and Policy Analysis, McMaster University, CRL Building, Room 229, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada. emmanuel.guindon@mcmaster.ca.ORCID 0000-0001-9561-5072

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo describe the extent to which New Brunswick residents reported having drug insurance coverage supplementary to Canadian Medicare; to examine associations between socioeconomic and demographic characteristics, health status, language identity, and having reported such coverage; and to document any changes in coverage associated with the introduction of the New Brunswick Drug Plan in 2014.

methodsWe used repeated cross-sectional data for New Brunswick from eight cycles of the Canadian Community Health Survey from 2007 to 2017 and undertook logistic regression analysis.

resultsWe found statistically significant, substantial and policy-relevant socioeconomic differences in the reporting of prescription drug insurance coverage among those 25-64 years and those ≥ 65 years of age, and an increasing reliance on private drug insurance over time. We found that individuals in the second decile of household income were particularly vulnerable to reporting neither public nor private drug coverage. The introduction of the New Brunswick Drug Plan in 2014 does not appear to have led to increased public drug coverage; however, from 2014, the decreasing trend in public drug coverage appears to have ceased. Those who reported lower health status usually had lower odds of reporting private drug coverage but higher odds of reporting public drug coverage. Driven by differences in private coverage, we found that relative to anglophones, francophones were less likely to report any drug coverage.

conclusionOur findings emphasize the shortcomings of drug insurance systems such as that introduced in New Brunswick and substantiate calls for a universal drug program. New Brunswick's increasing reliance on private drug insurance is of concern and warrants additional research.

Indexed as

Prescription DrugsAgedCanadaCross-Sectional StudiesHumansInsurance CoverageInsurance, Pharmaceutical ServicesNational Health ProgramsNew BrunswickPrescriptionsPrescription DrugsCanadaDrug insuranceHealth equityNew BrunswickSocioeconomic factors

Identifiers

PMID35488147
PMCPMC9263015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.